Dorian Therapeutics
Develops senoblockers, a novel class of therapeutics that target epigenetic regulators to reverse cellular senescence and restore stem cell activity. This approach addresses the decline in regenerative capacity and the accumulation of senescent cells, which are key contributors to age-related diseases.
- Biotechnology
Funding
Raised to date
$150KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
As organisms age, stem cell activity decreases, reducing regenerative capacity. Simultaneously, senescent cells accumulate, negatively impacting tissue function and contributing to age-related diseases.
Solution
Dorian Therapeutics developed senoblockers, a class of therapeutics designed to reverse cellular senescence and restore stem cell activity by targeting epigenetic regulators. Senoblockers reactivate programs of youthfulness and regeneration, addressing the underlying biological mechanisms of aging and related diseases. This approach aims to rejuvenate cells and tissues, offering a potential solution for age-associated conditions.
Target Audience
The primary target audience includes researchers and clinicians focused on developing treatments for age-related diseases.
Features
- Targets epigenetic regulators to reverse cellular senescence.
- Restores stem cell activity to enhance regenerative capacity.
- Designed to reactivate programs of youthfulness at the cellular level.